Related Experiment Video
Updated: May 24, 2026
19:57
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing
M A Martin1, T E Klein, B J Dong
1Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.
Clinical Pharmacology and Therapeutics
|March 2, 2012
Summary
Genetic screening for the Human Leukocyte Antigen B (HLA-B) *57:01 allele is crucial. This prevents life-threatening hypersensitivity reactions to the anti-HIV drug abacavir, improving patient safety.
Area of Science:
- Immunogenetics
- Pharmacogenomics
- Drug Hypersensitivity
Background:
- Human Leukocyte Antigen B (HLA-B) presents peptides to immune cells, vital for pathogen recognition.
- The HLA-B*57:01 allele is linked to hypersensitivity reactions to abacavir, an anti-HIV medication.
- Without genetic screening, abacavir hypersensitivity affects approximately 6% of patients, posing a significant risk.
Purpose of the Study:
- To provide updated recommendations for abacavir use based on HLA-B genotype.
- To reduce the incidence of severe hypersensitivity reactions to abacavir.
Main Methods:
- Analysis of HLA-B genotypes in patients prescribed abacavir.
- Correlation of HLA-B*57:01 presence with hypersensitivity reactions.
- Development of clinical guidelines based on genetic findings.
Main Results:
- The HLA-B*57:01 allele is a strong predictor of abacavir hypersensitivity.
- Genetic prescreening can identify individuals at high risk.
- Recommendations for abacavir therapy are informed by HLA-B genotype.
Conclusions:
- HLA-B genotyping is essential for safe abacavir prescribing.
- Implementing genetic screening guidelines minimizes drug hypersensitivity risks.
- Personalized medicine approaches, guided by pharmacogenomics, enhance patient outcomes.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...